ESCO1 and neoplasm: Paclitaxel, a highly effective chemotherapeutic agent utilized in the treatment of CC, has been recognized for its repression role in tumor progression in various cancer types through ferroptosis.[32] Considering the elevated expression of ESCO1 and TURORF and their involvement in the regulation of ferroptosis in CC cells, we sought to investigate whether silencing ESCO1 or TURORF influences the anti‐tumor effect of paclitaxel.